Title:  Three VC firms are investing in LegoChem

Publication: MoneyToday the Bell / Dong-Hee Kim

Date: 6 Nov 2014

Summary

·         Atinum Investment, InterVest, and Korea Investment Partners have decided to invest KRW 19 bn in LegoChem Biosciences to support its research and development.

·         Three VCs all see a growth potential in LegoChem’s pipelines: research projects including antibiotics (oxazolidinone, next-generation oxazolidinone, and gram-negative antibiotics), anti-coagulants, and next-generation ADC (antibody-drug conjugates) technologies are running well.

·         According to a person from Korea Investment Partners, the additional investment decision was taken with an expectation that LegoChem would achieve meaningful growth.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).